Author(s): Piotr Ska?ba, Dorota Kuglin, Anna D?bkowska-Hu?
Introduction. Adiponectin is a molecule that improves glucose tolerance and tissular insulin sensitivity. Furthermore, it demonstrates anti-atherogenic and anti-inflammatory properties. Common episodes in the course of PCOS are metabolic disorders such as obesity, and fat and carbohydrate metabolism. Findings of past studies suggest that adiponectin could play a potential role in the syndrome aetiopathogenesis, especially in the development of metabolic disorders. Materials and methods. Patients with diagnosed polycystic ovary syndrome were included in the study. The control group was composed of healthy women with regular menses. Within each of the groups patients were divided into subgroups on the ground of either normal body weight or obesity. Blood for tests was collected between the second and the fifth day of the menstruation cycle to evaluate adiponectin level, insulin resistance indices and patients’ BMI. Results. Mean patient age and mean BMI both in the study group and in the control group were comparable. HOMA index was significantly higher in obese patients than in patients of normal body weight in both groups. Having calculated Quicki index, statistically significant differences were found between the obese patients of the study group and the control group, and between both the groups when patients of normal body weight were compared. Conclusion. Significantly lower serum adiponectin levels were detected in the study group compared to the reference (control) group. Moreover, both in the study group and the reference group adiponectin levels were higher in normal body weight patients. No correlation has been found between insulin resistance indices, body weight, BMI and serum adiponectin level.